ADXS (Ayala Pharmaceuticals) Float Percentage Of Total Shares Outstanding: 42.50% (As of Sep. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADXS Ayala Pharmaceuticals Inc ADXS
12 GF Score
Price $0.60
View Full Analysis

What is Ayala Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Ayala Pharmaceuticals ADXS 12 Float Percentage Of Total Shares Outstanding is 42.50% as of Sep. 06, 2026. GuruFocus rates ADXS with a GF Score™ of 12/100.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ayala Pharmaceuticals's float shares is 18.10 Mil. Ayala Pharmaceuticals's total shares outstanding is 42.59 Mil. Ayala Pharmaceuticals's float percentage of total shares outstanding is 42.50%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ayala Pharmaceuticals's Insider Ownership is 2.66%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ayala Pharmaceuticals's Institutional Ownership is 0.02%.

ADXS
12GF Score
Ayala Pharmaceuticals Inc ADXS
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ayala Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Ayala Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=18.10/42.59
=42.50%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 42.50% mean?
Ayala Pharmaceuticals (ADXS) has a Float Percentage Of Total Shares Outstanding of 42.50% as of Sep. 06, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Ayala Pharmaceuticals and its competitors.
Is Ayala Pharmaceuticals' Float Percentage Of Total Shares Outstanding too high?
Ayala Pharmaceuticals' current Float Percentage Of Total Shares Outstanding is 42.50%. Overall, Ayala Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Ayala Pharmaceuticals' Float Percentage Of Total Shares Outstanding compare to SCPX and PBM?
Ayala Pharmaceuticals' Float Percentage Of Total Shares Outstanding of 42.50% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Ayala Pharmaceuticals and its competitors. Ayala Pharmaceuticals's current Float Percentage Of Total Shares Outstanding is 42.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ayala Pharmaceuticals stock overvalued right now?
Ayala Pharmaceuticals (ADXS) has a current Float Percentage Of Total Shares Outstanding of 42.50%. The current Float Percentage Of Total Shares Outstanding is 42.50%. Ayala Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Ayala Pharmaceuticals (ADXS), the current Float Percentage Of Total Shares Outstanding is 42.50% as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ayala Pharmaceuticals Business Description

Address 9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ, USA, 08852
Ayala Pharmaceuticals Inc is a clinical-stage oncology company whose primary clinical assets currently include aspacytarabine (BST-236), a novel proprietary anti-metabolite for first-line treatment in unfit acute myeloid leukemia (AML). BST-236 is a novel prodrug of cytarabine, enabling the delivery of high cytarabine doses with reduced systemic toxicity, creating a potential new backbone for AML combination regimens. It believes that its novel product candidates if approved, have the potential to transform treatment outcomes for patients suffering from solid and hematological cancers. These efforts are primarily focused on the development of ADXS-504, an Lm-based therapy for early-stage prostate cancer.
12GF Score

Get the complete analysis for ADXS

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.60
Price